Clarius Group LLC increased its position in Juno Therapeutics Inc (NASDAQ:JUNO) by 2.6% in the fourth quarter, HoldingsChannel reports. The firm owned 120,988 shares of the biopharmaceutical company’s stock after purchasing an additional 3,092 shares during the quarter. Juno Therapeutics accounts for 2.5% of Clarius Group LLC’s holdings, making the stock its 6th biggest holding. Clarius Group LLC’s holdings in Juno Therapeutics were worth $5,530,000 at the end of the most recent quarter.
A number of other large investors have also recently bought and sold shares of JUNO. Capital International Investors acquired a new position in Juno Therapeutics in the third quarter valued at approximately $256,339,000. Jennison Associates LLC boosted its stake in Juno Therapeutics by 162.0% in the third quarter. Jennison Associates LLC now owns 1,988,708 shares of the biopharmaceutical company’s stock valued at $89,213,000 after acquiring an additional 1,229,622 shares during the period. Orbimed Advisors LLC boosted its stake in Juno Therapeutics by 123.1% in the third quarter. Orbimed Advisors LLC now owns 2,041,608 shares of the biopharmaceutical company’s stock valued at $91,587,000 after acquiring an additional 1,126,400 shares during the period. Capital Guardian Trust Co. acquired a new position in Juno Therapeutics in the third quarter valued at approximately $37,400,000. Finally, Janus Henderson Group PLC acquired a new position in Juno Therapeutics in the third quarter valued at approximately $37,351,000. Institutional investors and hedge funds own 71.49% of the company’s stock.
In other news, CFO Steve Harr sold 8,750 shares of Juno Therapeutics stock in a transaction that occurred on Thursday, December 21st. The stock was sold at an average price of $44.76, for a total transaction of $391,650.00. Following the sale, the chief financial officer now owns 772,082 shares of the company’s stock, valued at $34,558,390.32. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, CEO Hans Edgar Bishop sold 270,250 shares of the business’s stock in a transaction that occurred on Tuesday, January 16th. The stock was sold at an average price of $46.17, for a total value of $12,477,442.50. Following the sale, the chief executive officer now directly owns 2,772,679 shares in the company, valued at approximately $128,014,589.43. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 473,031 shares of company stock worth $27,031,205. Corporate insiders own 15.08% of the company’s stock.
JUNO has been the subject of a number of research reports. Raymond James Financial lifted their target price on Juno Therapeutics from $45.00 to $61.00 and gave the company an “outperform” rating in a research note on Friday, November 3rd. Standpoint Research restated a “hold” rating on shares of Juno Therapeutics in a research note on Wednesday, January 24th. JPMorgan Chase & Co. restated a “hold” rating on shares of Juno Therapeutics in a research note on Thursday, January 11th. Wells Fargo & Co restated a “market perform” rating and issued a $63.00 target price (up from $54.00) on shares of Juno Therapeutics in a research note on Wednesday, January 17th. Finally, Barclays downgraded Juno Therapeutics from an “overweight” rating to an “equal weight” rating and lifted their target price for the company from $55.00 to $87.00 in a research note on Wednesday, January 24th. Two research analysts have rated the stock with a sell rating, sixteen have assigned a hold rating and three have assigned a buy rating to the stock. The stock presently has an average rating of “Hold” and an average target price of $51.20.
Shares of Juno Therapeutics Inc (NASDAQ:JUNO) opened at $85.10 on Tuesday. The firm has a market capitalization of $9,720.00, a P/E ratio of -25.10 and a beta of 3.42. The company has a current ratio of 4.77, a quick ratio of 4.77 and a debt-to-equity ratio of 0.01. Juno Therapeutics Inc has a twelve month low of $19.62 and a twelve month high of $86.28.
TRADEMARK VIOLATION NOTICE: This article was first posted by Stock Observer and is the property of of Stock Observer. If you are reading this article on another publication, it was copied illegally and reposted in violation of US and international copyright laws. The original version of this article can be read at https://www.thestockobserver.com/2018/02/20/juno-therapeutics-inc-juno-shares-bought-by-clarius-group-llc.html.
Juno Therapeutics Profile
Juno Therapeutics, Inc (Juno) is a biopharmaceutical company, which is focused on developing cellular immunotherapies for the treatment of cancer. The Company is developing cell-based cancer immunotherapies based on its chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies to genetically engineer T cells to recognize and kill cancer cells.
Want to see what other hedge funds are holding JUNO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Juno Therapeutics Inc (NASDAQ:JUNO).
Receive News & Ratings for Juno Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Juno Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.